Development of the PANVAC-VF vaccine for pancreatic cancer.
作者： Christian A Petrulio , Howard L Kaufman
关键词:
摘要: PANVAC™-VF is a vaccine regimen composed of priming dose recombinant vaccinia virus and booster doses fowlpox expressing carcinoembryonic antigen, mucin-1 triad costimulatory molecules (TRICOM), which include B7.1, intercellular adhesion molecule-1 leukocyte function-assocaited antigen-3. Vaccination administered by subcutaneous injection followed 4 days local adjuvant granulocyte–macrophage colony-stimulating factor at the vaccination site. The has been developed for patients with advanced pancreatic cancer now entered randomized Phase III clinical trial. This review will describe background poxvirus technology tumor development, detail key preclinical studies supporting regimen, trials current study, highlight challenges future obstacles to successful implementation PANVAC-VF cancer.
sci-hub.se 参考文章(74)
Howard L Kaufman, Seth Cohen, TG-4010 Transgene. Current opinion in investigational drugs. ,vol. 5, pp. 1319- ,(2004)
Joyce Taylor-Papadimitriou, Joy M. Burchell, Timothy Plunkett, Rosalind Graham, Isabel Correa, David Miles, Michael Smith, MUC1 and the immunobiology of cancer Journal of Mammary Gland Biology and Neoplasia. ,vol. 7, pp. 209- 221 ,(2002) , 10.1023/A:1020360121451
Vincenzo Bronte, Nicholas P. Restifo, Steven A. Rosenberg, Bernard Moss, Kari R. Irvine, Ronald S. Chamberlain, Jay B. Rao, Miles W. Carroll, IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression. Journal of Immunology. ,vol. 156, pp. 3357- 3365 ,(1996)
J A Kantor, J P McLaughlin, J W Hodge, S I Abrams, J Schlom, W L Shupert, Admixture of a Recombinant Vaccinia Virus Containing the Gene for the Costimulatory Molecule B7 and a Recombinant Vaccinia Virus Containing a Tumor-associated Antigen Gene Results in Enhanced Specific T-Cell Responses and Antitumor Immunity Cancer Research. ,vol. 55, pp. 3598- 3603 ,(1995)
Douglas W. Grosenbach, James W. Hodge, Jacqueline C. Barrientos, Jeffrey Schlom, Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Research. ,vol. 61, pp. 4497- 4505 ,(2001)
S Gillard, D Spehner, R Drillien, Mapping of a vaccinia host range sequence by insertion into the viral thymidine kinase gene Journal of Virology. ,vol. 53, pp. 316- 318 ,(1985) , 10.1128/JVI.53.1.316-318.1985
Jeffrey Schlom, Alicia Gómez Yafal, Matthias G. O. Lorenz, James W. Hodge, Linda Gritz, Helen Sabzevari, A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Research. ,vol. 59, pp. 5800- 5807 ,(1999)
Jeffrey Schlom, Judy A. Kantor, Joanne P. McLaughlin, John W. Greiner, Improved Immunotherapy of a Recombinant Carcinoembryonic Antigen Vaccinia Vaccine When Given in Combination with Interleukin-2 Cancer Research. ,vol. 56, pp. 2361- 2367 ,(1996)
Finn Oj, Kotera Y, Fontenot Jd, Pecher G, Metzgar Rs, Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients Cancer Research. ,vol. 54, pp. 2856- 2860 ,(1994)
John L. Marshall, Michael J. Hawkins, Kwong Y. Tsang, Ellen Richmond, James E. Pedicano, MingZhu Zhu, Jeffrey Schlom, Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. Journal of Clinical Oncology. ,vol. 17, pp. 332- 332 ,(1999) , 10.1200/JCO.1999.17.1.332